JAMP KETOTIFEN OPHTHALMIC DIN 02542722
Status: Marketed
Holder: JAMP PHARMA CORPORATION
Molecule: KETOTIFEN (KETOTIFEN FUMARATE)
Available to quote
Health Canada record
| Active ingredient(s) | KETOTIFEN (KETOTIFEN FUMARATE) 0.25 MG |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S01GX08 KETOTIFEN |
| Original market date | 21-Feb-2025 |
| Current status date | 21-Feb-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing KETOTIFEN (KETOTIFEN FUMARATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00577308 | ZADITEN | TEVA CANADA LIMITED | Tablet | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Marketed |
| 02172585 | ZADITEN - DPS 1MG/ML | NOVARTIS PHARMACEUTICALS CANADA INC | Drops | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Approved |
| 02242324 | ZADITOR | LABORATOIRES THEA | Solution | KETOTIFEN (KETOTIFEN FUMARATE) 0.25 MG | Marketed |
| 02400871 | KETOTIFEN OPHTHALMIC SOLUTION | STERIMAX INC | Solution | KETOTIFEN (KETOTIFEN FUMARATE) 0.25 MG | Dormant |
| 02176084 | NOVO-KETOTIFEN - SYR 1MG/5ML | NOVOPHARM LIMITED | Syrup | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Cancelled Post Market |
| 02230730 | NOVO-KETOTIFEN TAB 1MG | NOVOPHARM LIMITED | Tablet | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Cancelled Post Market |
| 02231679 | PMS-KETOTIFEN | PHARMASCIENCE INC | Syrup | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Cancelled Post Market |
| 02231680 | PMS-KETOTIFEN | PHARMASCIENCE INC | Tablet | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Cancelled Post Market |
| 00600784 | ZADITEN | TEVA CANADA LIMITED | Syrup | KETOTIFEN (KETOTIFEN FUMARATE) 1 MG | Cancelled Post Market |
| 02279223 | ZADITOR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | KETOTIFEN (KETOTIFEN FUMARATE) 0.25 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32014 | 2023-11-02 | Abbreviated New Drug Submission (ANDS) |